Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Ho-166-Radioembolisation vs Y-90-Radioembolisation
DRKS00014139Phase 4Terminated
- Sponsor
- University Hospital Magdeburg
- Start
- Mar 2018
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in colorectal cancer (CRC) and breast cancer comparing Y-90 SIR-Spheres radioembolisation with Ho-166 QuiremSpheres radioembolisation (2 arms). Primary endpoints: Safety of Ho-166 versus Y-90 radioembolisation and Efficacy of Ho-166 versus Y-90 radioembolisation. Started Mar 2018; status: terminated.
02
Drugs
holmium (166Ho) microspheresyttrium-90 resin microspheres
03
Conditions
colorectal cancer (CRC)breast cancer
Beyond the preview
Go deeper on DRKS00014139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00014139.